28285800|t|Perspectives on cardiovascular effects of incretin -based drugs: From bedside to bench, return trip
28285800|a|Recently, cardiovascular outcome trials with glucose -lowering drugs used in type 2 diabetes mellitus, namely glucagon-like peptide-1 receptor agonists (GLP-1RA), liraglutide and semaglutide, showed a reduction in cardiovascular events, which had not been observed in trials with other incretin -based drugs, such as lixisenatide or with dipeptidyl peptidase-4 inhibitors (DPP4i). Mechanisms underlying the observed cardiovascular differences between DPP4i and GLP1-RA, and across individual GLP1-RA are poorly understood. This review is aimed at collecting and summarizing available evidence from experimental and mechanistic studies on the action of GLP1-RA and DPP4i on the cardiovascular system, both deriving from clinical and pre-clinical sources. The results of cardiovascular outcome trials are interpreted on the basis of the experimental preclinical data available, paying particular attention to the heart failure results, and suggesting some novel intriguing hypotheses to explain some of the unexpected findings of cardioprotection of incretin -based drugs. In particular, we discuss the possible contribution to the incretin cardiovascular effects of a direct cardiac action of GLP-1 metabolites through GLP-1 receptor -independent pathways, and of DPP4 substrates other than GLP-1.
28285800	16	30	cardiovascular	T022	UMLS:C0007226
28285800	42	50	incretin	T103	UMLS:C1562292
28285800	58	63	drugs	T103	UMLS:C1254351
28285800	110	124	cardiovascular	T022	UMLS:C0007226
28285800	133	139	trials	T062	UMLS:C0008976
28285800	145	152	glucose	T103	UMLS:C0017725
28285800	163	168	drugs	T103	UMLS:C1254351
28285800	177	201	type 2 diabetes mellitus	T038	UMLS:C0011860
28285800	210	242	glucagon-like peptide-1 receptor	T103	UMLS:C0378073
28285800	243	251	agonists	T103	UMLS:C0243192
28285800	253	260	GLP-1RA	T103	UMLS:C0243192
28285800	263	274	liraglutide	T103	UMLS:C1456408
28285800	279	290	semaglutide	T103	UMLS:C3885068
28285800	314	335	cardiovascular events	T033	UMLS:C1320716
28285800	368	374	trials	T062	UMLS:C0008976
28285800	386	394	incretin	T103	UMLS:C1562292
28285800	402	407	drugs	T103	UMLS:C1254351
28285800	417	429	lixisenatide	T103	UMLS:C2973895
28285800	438	471	dipeptidyl peptidase-4 inhibitors	T103	UMLS:C1827106
28285800	473	478	DPP4i	T103	UMLS:C1827106
28285800	516	530	cardiovascular	T022	UMLS:C0007226
28285800	551	556	DPP4i	T103	UMLS:C1827106
28285800	561	568	GLP1-RA	T103	UMLS:C0243192
28285800	592	599	GLP1-RA	T103	UMLS:C0243192
28285800	628	634	review	T170	UMLS:C0282443
28285800	698	710	experimental	T062	UMLS:C0681814
28285800	715	734	mechanistic studies	T062	UMLS:C0681814
28285800	752	759	GLP1-RA	T103	UMLS:C0243192
28285800	764	769	DPP4i	T103	UMLS:C1827106
28285800	777	798	cardiovascular system	T022	UMLS:C0007226
28285800	869	883	cardiovascular	T022	UMLS:C0007226
28285800	892	898	trials	T062	UMLS:C0008976
28285800	935	947	experimental	T062	UMLS:C0681814
28285800	948	964	preclinical data	T170	UMLS:C1516606
28285800	1011	1024	heart failure	T038	UMLS:C0018801
28285800	1148	1156	incretin	T103	UMLS:C1562292
28285800	1164	1169	drugs	T103	UMLS:C1254351
28285800	1230	1238	incretin	T103	UMLS:C1562292
28285800	1239	1253	cardiovascular	T022	UMLS:C0007226
28285800	1274	1281	cardiac	T017	UMLS:C0018787
28285800	1292	1297	GLP-1	T103	UMLS:C0061355
28285800	1298	1309	metabolites	T103	UMLS:C0870883
28285800	1318	1332	GLP-1 receptor	T103	UMLS:C0378073
28285800	1346	1354	pathways	T038	UMLS:C1704259
28285800	1363	1367	DPP4	T103	UMLS:C0081937
28285800	1390	1395	GLP-1	T103	UMLS:C0061355